We are live on ! Find out more
DRRX

DURECT Corp

Delisted

DRRX was delisted on the 10th of September, 2025.

63 hedge funds and large institutions have $39.1M invested in DURECT Corp in 2014 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 14 increasing their positions, 19 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

14% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 7

0% more funds holding

Funds holding: 6363 (0)

26% less repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 19

44% less capital invested

Capital invested by funds: $70.3M → $39.1M (-$31.2M)

100% less funds holding in top 10

Funds holding in top 10: 10 (-1)

Holders
63
Holders Change
Holders Change %
0%
% of All Funds
1.68%
Holding in Top 10
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
New
8
Increased
14
Reduced
19
Closed
7
Calls
$9K
Puts
Net Calls
+$9K
Net Calls Change
-$33K

DRRX Hedge Fund Activity: Q4 2014 in Review

63 of the 3,751 institutional investors tracked by Wall St. Rank reported a position in DURECT Corp (DRRX) for Q4 2014, worth a combined $39.1M — down 44% from $70.3M a quarter earlier.

Buyers outnumbered sellers: 8 funds opened new DRRX positions and 7 closed out — a net gain of 1 holder — while 14 added to existing stakes and 19 trimmed.

The largest buyer was Wells Fargo, adding an estimated $63.6K. The largest seller was Sophrosyne Capital, exiting entirely with an estimated $1.77M sold.

  • 63 institutional investors held DURECT Corp (DRRX) as of Q4 2014, unchanged from Q3 2014.
  • Funds reported $39.1M of DURECT Corp stock for Q4 2014, down 44% quarter-over-quarter.
  • 8 funds opened new DURECT Corp positions in Q4 2014 and 7 closed out, a net change of +1 holder.
  • The largest DURECT Corp buyer in Q4 2014 was Wells Fargo, an estimated $63.6K added.
  • The largest DURECT Corp seller in Q4 2014 was Sophrosyne Capital, an estimated $1.77M sold.

Based on aggregated 13F filings for Q4 2014.